# A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

> **NCT06352424** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 23 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** BI 456906
- **DRUG:** BI 1820237
- **DRUG:** Placebo for BI 1820237
- **DRUG:** Placebo for BI 456906

## Key facts

- **NCT ID:** NCT06352424
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-30
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06352424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06352424, "A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06352424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*